Abstract 2972: Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity
Benjamin J. Drapkin(Southwestern Medical Center), Nicholas J. Dyson(Massachusetts General Hospital), Camilla L. Christensen(Dana-Farber Cancer Institute), Nima Abedpour(University of Cologne), Daniel A. Haber(Howard Hughes Medical Institute), Leica V. Sequist(Massachusetts General Hospital), Roman K. Thomas(University of Cologne), Joseph A. LiCausi(Harvard University), Anna F. Farago(Massachusetts General Hospital), Marina Kem(Massachusetts General Hospital), Martin Peifer(University of Cologne), Marcello Stanzione(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Mari Mino–Kenudson(Massachusetts General Hospital), Mehmet Toner(Center for Cancer Research), Alice T. Shaw(Dana-Farber Cancer Institute), Jun Zhong(Massachusetts General Hospital), Aaron N. Hata(Harvard University), David T. Myers(Harvard University), Julie George(University of Cologne), Tilak Sundaresan(Kaiser Permanente San Francisco Medical Center), Sarah Phat(Harvard University), Beow Y. Yeap(Harvard University), Ruben Dries(Boston University)
Cited by 1
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k